Compare BMEA & CURI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BMEA | CURI |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | United States |
| Employees | N/A | 42 |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 138.1M | 149.4M |
| IPO Year | 2021 | N/A |
| Metric | BMEA | CURI |
|---|---|---|
| Price | $1.40 | $3.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $9.83 | $5.83 |
| AVG Volume (30 Days) | ★ 1.2M | 555.0K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 10.36% |
| EPS Growth | ★ 69.19 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.91 |
| Revenue Next Year | N/A | $12.91 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $2.30 |
| 52 Week High | $3.07 | $7.15 |
| Indicator | BMEA | CURI |
|---|---|---|
| Relative Strength Index (RSI) | 45.33 | 59.22 |
| Support Level | $1.23 | $3.00 |
| Resistance Level | $1.45 | $3.56 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 47.57 | 98.94 |
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. The firm's products and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, and Others. The majority of the revenue comes from the direct business and Content licensing. Geographically, the company generates the majority of its revenue from the United States.